v3.25.4
Capital and funding - Summary of Combined Financial Information in Relation to HUL (Details) - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Disclosure of classes of share capital [line items]      
Non-current assets € 53,405 € 60,556  
Current assets 17,066 19,194  
Current liabilities (21,662) (25,234)  
Non-current liabilities (31,222) (31,961)  
Turnover 50,503 52,479 [1] € 51,680 [1]
Profit after tax 10,011 6,369 [1] 7,140 [2]
Equity at beginning of period (22,555) (20,764) (21,701)
Profit after tax (10,011) (6,369) [1] (7,140) [2]
Other comprehensive income 2,227 (1,521) [2] 1,883 [2]
Other movements in equity (107) [3] 136 2
Equity at end of period (17,587) (22,555) (20,764)
Non-controlling interests      
Disclosure of classes of share capital [line items]      
Profit after tax 542 625 653
Equity at beginning of period (2,565) (2,662) (2,680)
Profit after tax (542) (625) (653)
Other movements in equity (32) [3] 97 21
Equity at end of period (2,057) (2,565) (2,662)
Subsidiaries with material non-controlling interests | Hindustan Unilever Limited      
Disclosure of classes of share capital [line items]      
Non-current assets 4,968 6,478  
Current assets 1,561 2,125  
Current liabilities (1,594) (1,456)  
Non-current liabilities (1,307) (1,798)  
Turnover 6,253 6,607  
Profit after tax 940 1,167  
Total comprehensive income 110 1,318  
Net increase/(decrease) in cash and cash equivalents (163) 364  
Profit after tax (940) (1,167)  
Subsidiaries with material non-controlling interests | Hindustan Unilever Limited | Non-controlling interests      
Disclosure of classes of share capital [line items]      
Profit after tax 539 446  
Equity at beginning of period (2,044) (2,048)  
Profit after tax (539) (446)  
Other comprehensive income 6 3  
Dividend paid to the non-controlling interest 582 511  
Currency translation 306 (60)  
Other movements in equity 120 (4)  
Equity at end of period € (1,569) € (2,044) € (2,048)
[1] The 2024 and 2023 comparatives have been restated from those previously published to reflect the demerger of our Ice Cream business (see note 21).
[2] The 2024 and 2023 comparatives have been restated from those previously published to reflect the demerger of our Ice Cream business (see note 21).
[3] Includes the impact on the minority liability and non-controlling interest following the acquisition of Dr. Squatch and Minimalist, and the step-up acquisitions of Nutrafol, Welly and Equilibra.